Treatment with hydroxyurea led to more hematologic dose-limiting toxicities (DLTs) compared with placebo in patients with ...
Complete SAD/MAD data from the Phase 1 trial of DISC-3405 in healthy volunteers were presented. In the SAD portion of this trial, healthy males and females ages 18 to 65 were given a single dose of ...
Beam Therapeutics Inc. (NASDAQ:BEAM) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in ...
Blood disorders are a group of conditions that affect the production, function, or structure of blood cells, leading to ...
Positive updates across all programs, including updates from ongoing clinical studies and new translational data in preclinical models ...
J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...
The 48-week end points of the MANIFEST-2 study show improvements in spleen reduction, symptoms, bone marrow fibrosis, and ...
Beam Therapeutics reported promising trial data from seven sickle cell patients treated with their gene-edited therapy, ...
NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 ...
The treatment CS-101 uses innovative transformer Base Editing (tBE) technology to help people with severe diseases such as ...
The viruses that scare me are the ones I don’t know about.” Anthony Fauci, long-time director of the National Institute ...
Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced initial data from its ongoing Phase 1b study evaluating R2891, ...